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After 6 weeks of treatment with 17;6-estradiol, two distinct groups of female 
NZB/ NZW mice were identified. Group I females developed significant increases 
in serum f f 2 - ,  p- and y-globulins and had few serologic abnormalities. Serum glob- 
ulins did not increase in Group I1 females. This blunted response correlated 
with a pretreatment increase in the frequency of positive tests for ANA, LE 
phenomena and cryoproteins in 4-week-old Group II mice. 
Systemic lupus erythematosus (SLE) is 
an autoimmune disease that occurs pre- 
dominantly in women ( I ) ,  and symptoms of 
this disorder often appear during pregnan- 
cy or immediately postpartum (2). These 
clinical observations have stimulated re- 
peated attempts to define the role of estro- 
genic hormones in the pathogenesis of 
SLE. Recent reports of exacerbations of 
SLE (3), joint pain and swelling (4), and 
the occurrence of positive tests for antinu- 
clear antibodies or LE cells (4, 5) in wom- 
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en treated with oral contraceptives have 
also drawn attention to the possible in- 
teractions between female hormones and 
autoimmune disease. Clearly, adverse reac- 
tions to synthetic estrogen-progestogens are 
exceptional, since the majority of women 
using oral contraceptives do not demon- 
strate this response (6, 7). Precise identifica- 
tion of the hormonal, metabolic, or genetic 
processes responsible for these abnormali- 
ties would have important implications and 
help to define the specific host factors re- 
sponsible for the evolution of autoimmune 
disease. 
This study was designed to evaluate the 
effects of daily administration of a natural- 
ly occurring female hormone, 17-p-estradiol, 
on the course of autoimmune disease in 
the NZB/NZW mouse. First-generation 
offspring of matings between New Zealand 
Black and New Zealand White mice de- 
velop a disease resembling SLE character- 
ized by positive tests for antinuclear anti- 
bodies (ANA), LE cells and the develop- 
ment of immune-complex nephritis (8). Af- 
ter 6 weeks of treatment with estradiol, two 
district patterns of serum globulin response 
were identified in NZB/NZW mice. Group 
I females developed high levels of f f 2 - ,  p- 
and 7-globulins. Group I1 females showed 
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insignificant increases of ff2- and y-globulins 
during treatment. After these groups of 
mice were identified on the basis of their 
serum protein responses to estradiol, it was 
noted that a significantly larger number of 
Group I1 mice had demonstrated serologic 
abnormalities (ANA, LE cells, and/or ayo- 
proteins) before treatmen,t started. Hyper- 
gammaglobulinemia was induced in Group 
I females, but the early course of disease in 
these mice did not differ from that found 
in the other animals. 
MATERIALS AND METHODS 
Anlmolr. Breeding pairs of New Zealand Black 
mice and New Zealand White mice were supplied 
by Mr. William D. Hall, T h e  University of Otago, 
Dunedin, New Zealand. Each of our colonies is 
maintained by brother-sister matings. Swiss Webster 
mice were raised from breeding pairs purchased 
from the Spartan Company, Haslett, Michigan. 
Treotment Protocol. Daily subcutaneous injec- 
tions of 17-p-estradiol, 2.5 rg/kg body weight, were 
started when mice were 4 weeks old. Control mice 
received equivalent volumes of propylene glycol 
vehicle. Mice were bled from the orbital venoub 
plexus before injections were started. Littermate 
male and female mice were randomly assigned to 
treatment or control groups. In the first experi- 
ment, 10.1 1 NZB/NZW antl 6 Swiss Webster mice of 
each sex were bled after 6 weeks of injections and 
killed 2 weeks later at  12 weeks of age. After noting 
the serum y-globulin response in treated NZB/NZW 
females, 12 additional females were studied before 
antl after 6 weeks of treatment with 17-p-estradiol. 
In a second experimental group, 12 four-week-old 
NZB/NZW females were bled before, after 2 and 4 
weeks of treatment, and killed at  8 weeks of age. 
Serum protein determlnationr. Electrophoresis 
of 2 ,.Jiters of mouse serum on cellulose acetate 
strips was performed in a Shantlon tank at constant 
citrretit (2 mamp/strip) using Tris-barbital-sodium 
barbital buffer (pH 8.8). After staining, protein 
fractions were cut out and each was dissolved in a 
mixture of ch1oroform:absolute ethanol 9: 1, v/v. 
The  optical density (On) of each fraction was 
tleterminrtl using a Beckman DU-2 spectrophotom- 
eter, and the protein concentrations were calculated 
as described by Scherr (9). To check the accuracy 
of protein recovery, duplicate strips of cellulose 
acetate were loaded with known amounts of protein 
antl electrophoresis was performed. Comparison of 
OD of duplicate eluted strips showed that recovery 
was accomplished with an accuracy of .C 2%. Total 
serum protein was measured by a biuret method. 
Crystalline bovine serum albumin was u,Sd as 
standard. 
Serum IgG levels were determined by radial 
immunodiffusion in 1% agar containing 1% goat 
antimouse IgC.* This commercial antiserum was 
found by immunoelectrophoresis to contain a sec- 
ond precipitating antibody. Repeated cross absorp- 
tions with mouse red cell hemolysate removed this 
contaminating antibody from the antiserum to IgG. 
T h e  IgG standard was separated from whole mouse 
serum by ion-exchange shromatography on a dieth- 
ylaminoethyl (DEAE) cellulose column by the 
method of Fahey (10). Purity of the absorbed 
antiserum and the IgG standard was verified by 
i rn mu noelec t rophoresis. 
Serologlc Studies. Detection of ANA was ac- 
complished hy an indirect immunofluorescent 
procedure using conjugated goat antimouse 7s 7- 
globulint and human leukocytes as substrate (11). 
Direct LE cell tests were performed using blood 
collected in capillary tubes and allowed to clot. The  
clot was disrupted with a fine steel wire and 
incubated for 2 hours at 37°C (12). T h e  smeared 
buffy coat was stained with Wright’s stain. LE tests 
were considered positive if at least one typical LE 
cell was identified on a slide. In this study, the 
presence of at  least three pieces of typical extracel- 
lular nuclear material (ECM) noted on scanning 
the entire slide was also considered evidence of a 
positive LE reaction. Based on the work of Golden 
antl McDuffie (13). ECM was identified as masses 
of round, homogeneous or mottled well- 
circumscribed purplish-staining nuclear material 
produced during in vitro incubatiqn of the LE 
preparation. T o  test for the presence of cryopro- 
teins, aliquots of serum were harvested at room 
temperature and stored in capillary tubes a t  4°C 
and examined after 24 and 48 hours for the 
presence of a precipitate. T h e  test was considered 
positive for cryoproteins if the precipitate disap- 
peared on rewarming to 37°C. 
fKallestad Iziboratories, Minneapolis, Minn. 
tImmunology Inc, Glen Ellyn, Ill. 
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iiirtoiogy. Renal tissue fixed in Carnoy’s solu- 
tion was embedded in paraffin and 4-p sections were 
prepared. The tissue sections were stained with 
hematoxylin and eosin, and with Schiff sulfite 
leucofuchsin (PAS) (14) and examined by light 
microscopy. 
RESULTS 
Serum proteins 
In  Table 1, mean concentrations of the 
major serum protein fractions in treated 
and control NZB/NZW mice at 4 weeks of 
age are compared with values at 10 weeks 
of age. Serum levels of albumin, al-globu- 
lins, and p-globulins were similar a t  4 and 
10 weeks of age. Age-dependent increases of 
mean a,-globulins and y-globulins were 
noted in control females. Two distinctive 
patterns of serum protein response were 
found in 10-week-old female NZB/NZW 
mice after 6 weeks of treatment with 
17-p-estracliol. Based upon this response to 
estrogen, the mice were designated as be- 
longing to Group I or Group 11. I n  Group 
I females, there was an increase in levels of 
az-, p- and y-globulins. In  estrogen-treated 
Group I1 females, changes in a2- and 
7-globulins were no greater than the age- 
dependent alterations in these serum pro- 
tein fractions found in control females. 
Statistical analysis for cgroups with unequal 
numbers of individuals (15) demonstrated 
that post-treatment differences in Group I 
and Group I1 mice were significant. For 
a,-globulins f = 3.2 with P < 0.05; for 
p-globulins t = 2.5 with P < 0.05;* and for 
7-globulins t = 9.2 with P < 0.001. 
Individual NZB/NZW females could 
not be identified as Group I or Group I1 
responders unless they received at least 6 
weeks of treatment with estradiol. Treated 
*For evaluation and interpretation of t ,  see Sec 
4.9 (15). Given the similarities in a2-, p -  and 7-  
globulin values before treatment, these probabilities 
are based upon the chance of such divergence after 
6 weeks of treatment. 
and control NZB/NZW females in a sec- 
ond experimental group were bled before 
and after 2 and 4 weeks of treatment. T h e  
mean serum 7-globulin value after 2 weeks 
of treatment was 4.5 mg/ml. At 4 weeks, the 
mean level of y-globulins increased to 6.3 
mg/ml. The  mean responses of treated ani- 
mals at 2 weeks and at 4 weeks were not 
statistically different from those of controls 
( P  > 0.9 and P > 0.9, respectively). 
Serum proteins in male NZB/NZW mice 
are also listed in Table 1. Albumin levels 
were not affected by aging or by treatment 
with estradiol. An unexpected increase in 
al-globulins was observed in 10-week-old 
male controls. Mean increases in  levels of 
a2- and y-globulins occurred in both control 
and treated males. p-globulins were essen- 
tially unchanged. The  pattern of response 
of a2- and y-globulins in treated males was 
similar to the response noted in estrogen- 
treated Group I1 females. Hypergam- 
maglobulinemia was not found in treated 
males, and no NZB/NZW male demon- 
strated a Group I response to treatment 
with estradiol. 
Swiss Webster mice were studied to eval- 
uate the effects of estradiol on a second 
strain of mice that was not susceptible to 
the spontaneous development of autoim- 
mune disease. The  only significant differ- 
ence between males and females was found 
in the mean p-globulin response after 6 
weeks of treatment (males 13.7, females 7.7 
ing/ml; P < 0.025). OtherGise, mean serum 
protein values for equal numbers of mice 
of both sexes were similar. As observed in 
NZB/NZW mice, there were no changes in 
albumin and al-globulin levels that could 
be ascribed to estrogen treatment. Treat- 
ment with estradiol did produce a mean 
increase in the level of a2-globulins from 
6.3 to 12.8 mg/ml in male and female mice. 
The  increase in serum y-globulin levels was 
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similar in control (3.2 to 7.1 mg/ml) and in  
estradiol-treated mice (4.0 to 7.8 mglml). In  
contrast to female NZB/NZW mice, there 
was no evidence that the serum 7-globulin 
response in either male or female Swiss 
Webster mice was differentially affected by 
6 weeks of treatment with 17-p-estradiol. 
To verify measurements of total serum 
7-globulins by the Scherr procedure, IgG 
levels were determined by radial immuno- 
diffusion using 35 specimens of sera from 
29 female NZB/NZW mice. The  mean IgG 
value in 15 pretreatment sera obtained 
from 4-week-old hybrid females was 1.2 
mg/ml. This represented 63% of the total 
7-globulin found in the serum of these 
animals by ,colorimetric measurement of 
the y-globulin fraction separated by cellu- 
lose acetate electrophoresis. IgG levels were 
increased in older mice (2.9-6.6 mglml). In  
14 estrogen-treated females the radial im- 
munodiffusion measurements of IgG were 
concordant with the total 7-globulin levels 
determined by the method of Scherr. In  
these animals, the mean serum IgG concen- 
tration accounted for 88 to 95% of the 
total -,-globulins. 
Antinuclear antibodies, LE cell tests 
and cryoproteins 
Positive tests for ANA, LE cells and/or 
cryoproteins in individual female NZB/ 
NZW mice are recorded in Table 2. At 
the beginning of the study, 4-week-old 
female littermates were assigned to either 
control or estrogen treatment groups with- 
out knowledge of their pretreatment sero- 
logic status. After 6 weeks of estradiol ther- 
apy, Group I and Group I1 females were 
identified on the basis of their serum pro- 
tein responses. At that time, analysis 
showed that 7 of the 13 females in Group 
I1 had at least one serologic abnormality 
before treatment. Only a single serologic 
Table 1. Serum Albumin, aI-, a2-, 8- and ?-Globulins in Control and 
17-p-Estradiol Treated NZB/NZW Mice 
ai ff? P Y 
No' Albumin Globulins Globulins Globulins Globulins 
Age of 
(wk) mice mg/ml 
NZBJNZW Females 
Controls 4 11 3 1 . 2 f 1 . 4 *  4 . 5 + 0 . 4  7 . 0 f 0 . 6  5 . 4 + 0 . 3  3 . 2 f 0 . 4  
Controls 10 11 3 4 . 0 f 0 . 9  5 . 4 f 0 . 6  8 . 3 f 0 . 6  5 . 2 f 0 . 2  5 . 0 f 0 . 3  
Treated 
Before Treatment 4 23 2 9 . 1 f 1 . 1  3 . 9 + 0 . 2  6 . l f 0 . 3  5 . 5 f 0 . 3  3 . 3 f 0 . 4  
After Treatment? 
Group I 10 10 3 1 . 5 f 2 . 4  5 . 6 f 0 . 5  1 3 . 3 f 1 . 2  9 . 1 + 1 . 6  9 . 7 f 0 . 5  
Group II 10 13 2 9 . 2 f 1 . 0  4 . 4 + 0 . 3  8.2f0.6 5 . 3 f 0 . 3  4 . 9 f 0 . 2  
Controls 4 9$ 27.7f 1 . 4  4 .9+ 0.5 6 . 0 f  0.5 5 . 5 f  0.3 3 .4f  0.5 
Controls 10 9 2 6 . 7 f 1 . 1  9 . 0 f 1 . 0  l l . O f l . l  5 . 6 f 0 . 6  5 . 4 f 0 . 3  
Treated 
Before Treatment 4 85 2 7 . 3 f 0 . 6  4 . 0 f 0 . 4  5 . 9 f 0 . 6  4 . 9 f 0 . 2  2 . 3 f 0 . 3  
After Treatment 10 8 2 8 . 7 f 1 . 8  5 . 3 + 0 . 8  9 . 1 f 0 . 9  5 . 5 f 0 . 5  5 . 4 f 0 . 1  
NZBJNZW Males 
* Mean f 1 SE 
* Treated with 17-p-estradiol for 6 weeks (2.5 pg/kg/day) 
$ One mouse died at  t ime of initial bleeding 
(i Two mice died at t ime of init ial bleeding 
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Table 2. Antinuclear Antibodies, LE Cell Reactions, and Cryoproteins in Control and 
17-fl-Estradiol Treated Female NZB/NZW Mice* 
Numbers of 
No. of Anti- Positive mice with 
Age mice nuclear LE cell Cryo- serologic 
Group (wk) tested antibodies tests proteins abnormalities 
Controls 4 11 3 0 0 3 
Controls 10 11 1 0 0 1 
Before Treatment 
Group I 4 10 1 0 0 1 
Group I I  4 13 4 3 7 
Group I 10 10 1 1 1 3 
Group II 10 13 3 1 2 5 
After Treatment1 
* One 10-week-old control NZB/NZW male and one 10-week-old treated Swiss Webster female were 
ANA-positive. There were no other positive serologic tests in  NZB/NZW males or Swiss Webster mice 
t Treated with 17-13-estradiol for 6 weeks (2.5 pg/kg/day) 
abnormality was found before treatment in 
the 10 Group I mice. T h e  difference in the 
numbers of female mice with serologic ab- 
normalities before treatment in Group I 
and Group I1 was significant (P < 0.05). 
Therefore, clustering of pretreatment sero- 
logic abnormalities in Group I1 animals 
correlated with the absence of serum pro- 
tein response to estradiol. 
After 6 weeks of treatment with estrogen, 
the occurrence of serologic abnormalities 
in control, Group I and Group I1 mice was 
similar. One 10-week-old control 
NZB/NZW male and one 10-week-old 
treated Swiss Webster female were ANA 
positive. Detailed examination of the num- 
bers of positive tests for ANA, LE cells 
and cryoproteins in individual mice before 
and after treatment failed to show that 
17-p-estradiol either stimulated or  s u p  
pressed the appearance of early serologic 
abnormalities in these animals. 
Renal histology 
Kidneys were removed at autopsy from 
18 treated and control NZB/NZW females 
and tissue sections were examined by light 
microscopy. These animals had received 
estradiol or propylene glycol for 4 weeks 
(11 mke) and 8 weeks (7 mice). They were 
8 and 12 weeks of age, respectively, when 
they were killed. Two examiners, unaware 
of the treatment status of the mice, read 
the slides independently. Although overt 
renal disease is said to develop between 4 
and 6 months of age in hybrid females (8), 
in this study definite histologic abnormali- 
ties were found in the kidneys of treated 
and control mice at 2 and 3 months of age. 
Mice in the younger age group demonstrat- 
ed both hypercellularity and thickening of 
the mesangial stalk. In 3-month-old hybrid 
females there was swelling and diffuse hy- 
percellularity of glomeruli, and focal areas 
of basement membrane thickening were 
found in PAS-stained sections. There was 
no conclusive evidence that these early 
renal abnormalities were influenced by 
treatment with low doses of 17-pestradiol 
for 8 weeks. 
DISCUSSION 
A unique finding in this study was the 
division of female NZB/NZW mice into 2 
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groups based on their serum a2-, p- and 
7-globulin responses to 6 weeks of parenter- 
a1 treatment with very low doses of 17-p-es- 
tradiol (2.5 g/kg/day). These two groups 
were further distinguished by a clustering 
of pretreatment serologic abnormalities in 
the female mice that failed to demonstrate 
an increase in serum proteins after 6 weeks 
of treatment with estradiol. 
Group I females responded to estrogen 
treatment with a threefold increase in 
serum 7-globulins. Significant increases in 
a2- and p-globulins were also observed. 
Based on the work of others, this response 
is expected in rodents. Varga found in- 
creased levels of a-, p- and 7-globulins in 
rats treated with estrogen (16). Treatment 
of guinea pigs with diethylstilbestrol has 
been found to stimulate increased levels of 
serum 7-globulins (17). In  our study, estra- 
diol treatment stimulated increases of 
a2-globulins in Swiss Webster mice but 
7-globulins were not increased in this 
strain. Group I1 NZB/NZW females-like 
NZB/NZW males-showed no increase in 
serum 7-globulin levels after treatment with 
17-p-estradiol. Work is currently in progress 
to define the effects of long-term treatment 
with estradiol in Group I and Group I1 
female NZB/NZW mice. 
In the current study, analysis of the 
frequency of positive tests for ANA, LE 
cells and cryoproteins showed that these 
serologic abnormalities were most common 
in 4-week-old female Group I1 mice before 
treatment with estradiol was started. This 
finding suggests that female hybrid mice 
that demonstrate early serologic markers of 
autoimmune disease are less responsive to 
the stimulating effects of estradiol on serum 
globulins. Studies by others (17-19) suggest 
that estrogen can either stimulate or s u p  
press immunologic phenomena in experi- 
mental animals. This may be related to the 
species of animal, the maturity of the ani- 
mal and the dose and duration of treat- 
ment. There was no evidence in this study 
that estradiol induced or suppressed ANA, 
LE tests or cryoproteins. Furthermore, 
there was no histologic evidence that 8 
weeks of low-dose estrogen administered to 
young NZB/NZW females accelerated the 
initial appearance of renal disease in either 
Group I or Group I1 mice. 
A1 though hypergammaglobulinemia is 
commonly considered one of the hallmarks 
of autoimmune disease, estrogen-induced 
hypergammaglobulinemia did not appear 
to accelerate the spontaneous development 
of disease in NZB/NZW mice. This is 
based upon failure to find increased num- 
bers of serologic abnormalities or histologic 
evidence of accelerated renal disease in 
Group I animals. Thus, 17-p-estradiol may 
produce a nonspecific stimulation of total 
serum y-globulins without augmenting im- 
munologic or biochemical reactions of crit- 
ical importance in the evolution of 
NZB/NZW disease. Immune deficiency 
states have been shown to correlate with an 
increased incidence of autoimmune disor- 
ders and neoplasia (20,21). The clustering 
of autoimmune abnormalities in Group I1 
mice suggests that a blunted host response 
may in some instances be more important 
in the evolution of autoimmune disease 
than a hyperreactive state. 
The current investigation demonstrates 
that exogenous estradiol treatment in a 
host uniformly predisposed to develop im- 
munopathologic disease produces at least 
two patterns of response. The target organ 
effects of this hormone are conditioned by 
a number of metabolic factors (16, 17,19), 
even in the offspring of two inbred strains 
of mice. Undoubtedly, the mechanism re- 
sponsible for the apparent provocative 
effect of estrogen in drug-induced and 
spontaneous autoimmune disorders in hu- 
mans is equally complex (1-7). Neverthe- 
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less, the current findings strongly suggest 
that  this hormone effects the immunologi- 
cally susceptible female more selectively 
than the male. T h i s  differential response i n  
the female NZB/NZW mouse offers a n  
opportunity to  examine in more detail the 
relevant extrinsic or immunogenetic deter- 
minants (8, 22, 23) important in path- 
ogenesis of au to immune disease in this 
experimental model. Chemical manipula- 
tion of the  early phase of prototype disease 
i n  the NZB/NZW mouse should provide 
new insight in to  the  host factors that  con- 
trol the evolution of the lesions that char- 
acterize h u m a n  systemic lupus erythemato- 
sus. 
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